Kiora Pharmaceuticals (KPRX) Other Working Capital Changes (2017 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Other Working Capital Changes came in at -$41953.0 in Q1 2026, down 239.7% YoY from $30030.7 in Q1 2025, and down 103.19% on a QoQ basis from $1.3 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 10 years of Other Working Capital Changes data on file, last reported at -$41953.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 239.7% year-over-year to -$41953.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 121291.36% YoY) and the FY2025 annual result came in at $1.2 million, changed N/A from the prior year.
- Other Working Capital Changes eased to -$41953.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.8 million in Q4 2024 to a low of -$1.2 million in Q3 2025.
- A 5-year average of $85496.9 and a median of $8322.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2025 — Other Working Capital Changes soared 3659.35% — and 2026, when it tumbled 239.7%.
- Tracing KPRX's Other Working Capital Changes over 5 years: stood at $21155.0 in 2022, then surged by 313.36% to $87447.0 in 2023, then slumped by 59.95% to $35026.0 in 2024, then soared by 3659.35% to $1.3 million in 2025, then tumbled by 103.19% to -$41953.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$41953.0 (Q1 2026), $1.3 million (Q4 2025), and -$27965.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40,660.00 |
| Jun 30, 2026 | -40,660.00 |
| Jun 30, 2026 | -40,660.00 |
| Mar 31, 2026 | -41,953.00 |
| Mar 31, 2026 | -41,953.00 |
| Mar 31, 2026 | -41,953.00 |
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2025 | 1.32 Mn |
| Sep 30, 2025 | -27,965.00 |
| Sep 30, 2025 | -27,965.00 |
| Sep 30, 2025 | -27,965.00 |
| Jun 30, 2025 | -26,435.00 |
| Jun 30, 2025 | -26,435.00 |
| Jun 30, 2025 | -26,435.00 |
| Mar 31, 2025 | -12,350.00 |
| Mar 31, 2025 | -12,350.00 |
| Mar 31, 2025 | -12,350.00 |
| Dec 31, 2024 | 35,026.00 |
| Dec 31, 2024 | 35,026.00 |